This is a working overview of Regulatory status, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-26. Anything still debated is marked as such rather than presented as settled.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
16 April – Scientists at the Riken institute demonstrate "advanced dual-chirped optical parametric amplification", which provides a 50-fold increase in the energy of single-cycle laser pulses. This new technique may advance the development of attosecond lasers. 23 April – The world's largest 3D printer, dubbed Factory of the Future 1.0 (FoF 1.0), is presented by the University of Maine. Using thermoplastic polymers, the machine can print objects as large as 96 feet (29 m) long by 32 feet (9.8 m) wide by 18 feet (5.5 m) high, at a rate of 500 pounds (230 kg) per hour. 24 April – Demonstration of synthetic diamond created at 1 atmosphere of pressure in around 150 minutes without needing seeds. 25 April – The first meta-analysis of 665 trials of conservation action such as invasive species control measuring biodiversity is published. 26 April – mRNA-4157/V940, the first personalised melanoma vaccine based on mRNA, enters a final-stage Phase III trial. 29 April Timothy A. Coleman, with the University of Alabama in Huntsville, Richard L. Thompson with the NOAA Storm Prediction Center, and Dr. Gregory S. Forbes, a retired meteorologist from The Weather Channel publish an article to the Journal of Applied Meteorology and Climatology stating, "it is apparent that the perceived shift in tornado activity from the traditional tornado alley in the Great Plains to the eastern U.S. is indeed real". Physicists outline how a subluminal warp drive that does not require exotic negative energy may be possible.
=== Data interpretation === The most common data interpretation is based on the Fresnel formulas, which treat the formed thin films as infinite, continuous dielectric layers. This interpretation may result in multiple possible refractive index and thickness values. Usually only one solution is within the reasonable data range. In multi-parametric surface plasmon resonance, two SPR curves are acquired by scanning a range of angles at two different wavelengths, which results in a unique solution for both thickness and refractive index. Metal particle plasmons are usually modeled using the Mie scattering theory. In many cases no detailed models are applied, but the sensors are calibrated for the specific application, and used with interpolation within the calibration curve.
In 1966, he and other musicians from the Boston folk scene formed a group called the International Submarine Band. In 1967, after briefly residing in the Kingsbridge section of the Bronx, they moved to Los Angeles. Following several lineup changes, the band signed with Lee Hazlewood's LHI Records, where they spent late 1967 recording Safe at Home. The album contains one of Parsons' best-known songs, "Luxury Liner", and an early version of "Do You Know How It Feels," which he revised later in his career. Safe at Home would remain unreleased until mid-1968, by which time the International Submarine Band had broken up. The International Submarine Band appeared in the Peter Fonda film The Trip (1967) as a performing band in one of the clubs. Their song "Lazy Days" was offered for the film's soundtrack, but the soundtrack was done by Mike Bloomfield's Electric Flag. In 1967, Peter Fonda recorded a version of Parsons' song "November Nights" titled "November Night". The song was released as a single in March 1967, with Donovan's "Catch the Wind" on the B side.
Sources: en.wikipedia.org
Save for a brief mention in the Barrie Examiner, it was the first time Carrey received significant mainstream corporate media coverage and the glowing praise in one of Canada's highest-circulation dailies created demand for his impressionist stand-up act throughout the country. In April 1981, Carrey appeared in an episode of the televised stand-up show An Evening at the Improv. That summer, he landed one of the main roles in Introducing... Janet, a made-for-TV movie that premiered in September 1981 on the CBC drawing more than a million viewers for its first airing in Canada. Playing a struggling impressionist comic Tony Moroni, it was Carrey's first acting role. The CBC promotion the movie had received as well its subsequent high nationwide viewership further solidified the youngster's comedic status in the country; by the time the movie finished its CBC run of repeats several years later, its title for the home video release on VHS was changed to Rubberface in order to take advantage of the comic's by then established prominence for doing elaborate contortionist impressions. Making more comedy club appearances in the United States, Carrey was noticed by comedian Rodney Dangerfield who signed Carrey to open his tour performances. By December 1981, a well-known comic in Canada, Toronto Star reported about Carrey waiting for a United States work permit having received interest from Johnny Carson's Tonight Show, largely off his reputation from Canada.
== Bibliography == Wergedahl, H; Liaset, B; Gudbrandsen, OA; Lied, E; Espe, M; Muna, Z; Mørk, S; Berge, RK (2004). "Fish protein hydrolysate reduces plasma total cholesterol, increases the proportion of HDL cholesterol, and lowers acyl-CoA:cholesterol acyltransferase activity in liver of Zucker rats". The Journal of Nutrition. 134 (6): 1320–7. doi:10.1093/jn/134.6.1320. PMID 15173391. Wu, Hui-Chun; Chen, Hua-Ming; Shiau, Chyuan-Yuan (2003). "Free amino acids and peptides as related to antioxidant properties in protein hydrolysates of mackerel (Scomber austriasicus)". Food Research International. 36 (9–10): 949–957. doi:10.1016/S0963-9969(03)00104-2. INIST 15251156. Marchbank, T.; Limdi, J. K.; Mahmood, A.; Elia, G.; Playford, R. J. (2008). "Clinical trial: Protective effect of a commercial fish protein hydrolysate against indomethacin (NSAID)-induced small intestinal injury". Alimentary Pharmacology & Therapeutics. 28 (6): 799–804. doi:10.1111/j.1365-2036.2008.03783.x. PMID 19145735. S2CID 31397. Nesse, Knut Olav; Nagalakshmi, A. P.; Marimuthu, P.; Singh, Mamta (2011). "Efficacy of a Fish Protein Hydrolysate in Malnourished Children". Indian Journal of Clinical Biochemistry. 26 (4): 360–5. doi:10.1007/s12291-011-0145-z. PMC 3210250. PMID 23024471. Kristinsson, Hordur G.; Rasco, Barbara A. (2000). "Fish Protein Hydrolysates: Production, Biochemical, and Functional Properties". Critical Reviews in Food Science and Nutrition. 40 (1): 43–81. doi:10.1080/10408690091189266. PMID 10674201. S2CID 28085824. Webb, K. E.; Bergman, E. N. (1991).
kinetochore A disc-shaped protein complex which assembles around the centromere of a chromosome during prometaphase of mitosis and meiosis, where it functions as the attachment point for microtubules of the spindle apparatus.
=== NutraSweet Company === In 1985, Monsanto bought G.D. Searle, and the aspartame business became a separate Monsanto subsidiary, NutraSweet. In March 2000, Monsanto sold it to J.W. Childs Associates Equity Partners II L.P. European use patents on aspartame expired beginning in 1987, with the US patent following suit in 1992.
Sources: en.wikipedia.org
=== Maxim Alonso === Maxim Alonso (Nicholas Bishop) is a hedge fund manager and old family friend of Yasmin's, placed in charge of overseeing her father Charles' assets. Maxim has a tense, quasi-brotherly relationship with Yasmin throughout series 1, especially after a client meeting with him is derailed by the misbehavior of Yasmin's abusive boss Kenny. In series 2, Maxim's fund goes bankrupt, prompting him to throw an excessive, drug-fueled party where and Yasmin end up having sex. While initially continuing their tryst, Yasmin grows distant from Maxim after becoming privy to Charles' numerous extramarital affairs and subsequent NDA settlements, which she is angry at Maxim for not telling her about. Maxim later drunkenly tries to force himself on Yasmin in bed, causing her to cut ties with him. In series 3, Maxim reaches out to Yasmin while camping in Northern California to tell her that Hanani Publishing was complicit in Charles' sexual misconduct, providing several of his victims with sham jobs in exchange for their silence. He explains that the company wants to make Yasmin the face of the scandal to hide their own involvement.
== Forensic science and humanitarian work == The International Committee of the Red Cross (ICRC) uses forensic science for humanitarian purposes to clarify the fate of missing persons after armed conflict, disasters or migration, and is one of the services related to Restoring Family Links and Missing Persons. Knowing what has happened to a missing relative can often make it easier to proceed with the grieving process and move on with life for families of missing persons. Forensic science is used by various other organizations to clarify the fate and whereabouts of persons who have gone missing. Examples include the NGO Argentine Forensic Anthropology Team, working to clarify the fate of people who disappeared during the period of the 1976–1983 military dictatorship. The International Commission on Missing Persons (ICMP) used forensic science to find missing persons, for example after the conflicts in the Balkans. Recognising the role of forensic science for humanitarian purposes, as well as the importance of forensic investigations in fulfilling the state's responsibilities to investigate human rights violations, a group of experts in the late-1980s devised a UN Manual on the Prevention and Investigation of Extra-Legal, Arbitrary and Summary Executions, which became known as the Minnesota Protocol. This document was revised and re-published by the Office of the High Commissioner for Human Rights in 2016.
At the Game Developers Conference in March 2015, Valve and Taiwanese electronics company HTC unveiled SteamVR and the HTC Vive—a virtual reality platform and a virtual reality headset. The platform would be distinguished by its "Lighthouse" motion tracking system, where sensors on the headset and its included motion controllers read the position of two base station devices mounted in the play area. This would allow for "room-scale" VR experiences, where the player would not be required to remain in a stationary position in front of a camera and would be able to freely walk around the space. In November 2017, Microsoft added beta support for the SteamVR service for Windows Mixed Reality headsets. In June 2019, Valve released its own VR headset, known as the Valve Index, positioned as a higher-end device with wider field of view and higher refresh rate. They were accompanied by updated motion controllers, which are strapped against the user's palms and have sensors to detect input pressure and individual fingers. In November 2025, Valve announced the Steam Frame, a standalone VR headset.
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.